ArticleJournal of thoracic disease2022

Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.

Xiaohui Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.